Clinical trials
Breast Cancer Screening clinical trials
Below are recruiting breast cancer screening clinical trials, each written for real people, not researchers. We’re tracking 609 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07159451RecruitingPhase 2
Elacestrant for premenopausal women with early breast cancer
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
VillejuifAges 18 years+ - NCT07152782RecruitingPhase 2
T-DXd with or without neratinib for HER2+ breast cancer brain metastases
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
ShanghaiAges 18–70 - NCT07150208RecruitingPhase 2
T-DXd with or without Avastin for HER2-low breast cancer that spread to the brain
This trial tests a combination of two targeted drugs (T-DXd and bevacizumab) for people with HER2-low breast cancer that has spread to the brain. It aims to see if adding bevacizumab helps the main drug work better against brain metastases.
ShanghaiAges 18–70 - NCT07121972Recruiting
Validating AI for breast cancer risk prediction
This trial uses an AI model called Mirai to identify women at high risk for breast cancer based on their mammograms. If you are eligible, you may be invited for a breast MRI to better understand your risk.
San Diego, CaliforniaAges 40–89 - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
Huntsville, AlabamaAges 18 years+ - NCT07095023Recruiting
Oral chemo and targeted therapy before breast cancer surgery
This trial tests a combination of an oral chemotherapy pill (paclitaxel) with two targeted antibodies (pertuzumab and trastuzumab) given before surgery for HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07095114Recruiting
Disappearing markers for daily breast radiation
This study tests whether small disappearing ink marks can be used to guide daily radiation treatments for breast cancer. It may help make radiation more precise and comfortable.
Detroit, MichiganAges 18 years+ - NCT07076147Recruiting
Breast cancer screening follow-up for moderate-risk women
This study looks at how well women with a moderate risk of breast cancer follow their screening recommendations (like yearly MRI or mammogram). It may help women who have certain genetic variants or a higher calculated risk stay on top of their breast health.
Los Angeles, CaliforniaAges 30–75 - NCT07075679Recruiting
AI vs double reading for breast cancer screening
This study compares a single radiologist reading your mammogram with help from artificial intelligence (AI) to the standard method of two radiologists reading it. The goal is to see if AI-assisted reading is just as good at finding cancer while saving time and resources.
OlomoucAges 45–69 - NCT07067138Recruiting
Genetic testing to guide treatment for advanced breast cancer
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
Bethesda, MarylandAges 18–120 - NCT07067788Recruiting
Comparing a new imaging method for breast calcifications
This study tests a new imaging technique to better see suspicious calcifications found during a mammogram. If you have these calcifications, this might help doctors learn more about them.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07009093Recruiting
Mobile app for young women with breast cancer
This study tests a mobile app called Mighty Pro to help young women with breast cancer manage stress. It is for women ages 18–45 who are patients at a specific cancer center and feel some distress.
Charlotte, North CarolinaAges 18–45 - NCT07008781Recruiting
Student-led program to boost cancer screening in families
This study tests whether a program led by students can help more families get cancer screenings. If you are a high school student and have an adult family member who needs a screening, you may be able to join together.
New Brunswick, New JerseyAges 15–80 - NCT07002177RecruitingPhase 1/Phase 2
Combination therapy study for ER+/HER2- breast cancer
This trial tests a new drug called FWD1802 combined with other treatments for people with a certain type of advanced breast cancer (ER-positive, HER2-negative). It aims to find better options if standard treatments have stopped working or aren't suitable.
ShanghaiAges 18–75 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06934239RecruitingPhase 4
AI-assisted vs. standard mammograms for breast cancer screening
This trial compares standard mammograms with mammograms aided by artificial intelligence (AI) to see if AI helps find breast cancer more accurately and reduces unnecessary callbacks. If you're 18 or older and getting a routine screening mammogram at one of the six participating health systems, you may be eligible.
Los Angeles, CaliforniaAges 18 years+ - NCT06938555Recruiting
Can extending nightly fasting improve sleep and thinking in breast cancer survivors?
This study tests whether eating all your meals within a shorter window each day (prolonged nightly fasting) can help improve sleep and thinking skills in breast cancer survivors who have memory or concentration problems.
Phoenix, ArizonaAges 18 years+ - NCT06917313RecruitingPhase 2
Fezolinetant for hot flashes in women with breast cancer on hormone therapy
This trial tests a drug called fezolinetant to see if it reduces hot flashes in women with HR+ breast cancer who are on hormone therapy (like tamoxifen or aromatase inhibitors). You need to be postmenopausal and having at least 7 moderate to severe hot flashes a day.
New Haven, ConnecticutAges 18 years+ - NCT06914440RecruitingPhase 2
Radiation and immunotherapy before surgery for HR+/HER2- breast cancer
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
Xi'an, Shannxi ProvinceAges 18–75 - NCT06665178RecruitingPhase 2
Testing SG after T-DXd in ER+/HER2-low metastatic breast cancer
This trial tests whether a different chemotherapy drug, called sacituzumab govitecan (SG), can help people with ER+/HER2-low metastatic breast cancer who have already been treated with trastuzumab deruxtecan (T-DXd). It also looks at genetic markers in your tumor to predict who might benefit from SG.
Vancouver, British ColumbiaAges 18 years+ - NCT06892275Recruiting
Helping high-risk women decide about breast MRI
This study tests a decision aid to help women at high risk for breast cancer decide whether to get a screening MRI. It is designed for Black and Latina women who have had a normal mammogram in the past year.
Washington D.C., District of ColumbiaAges 18–74 - NCT06889688RecruitingPhase 3
New drug combo vs. chemo for advanced triple-negative breast cancer
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06867484Recruiting
Breast re-irradiation after second lumpectomy
This trial tests whether giving a second round of radiation to the breast after a lumpectomy for a recurrence is safe and effective. It is for people with a specific type of breast cancer (ER+HER2-) who meet strict criteria regarding prior radiation and tumor characteristics.
Boca Raton, FloridaAges 40 years+
Hear when a new Breast Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer screening?
- Yes. Clin2 currently lists 609 recruiting breast cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.